ImmunityBio (IBRX) Current Leases (2016 - 2026)

ImmunityBio (IBRX) has 11 years of Current Leases data on file, last reported at $7.6 million in Q1 2026.

• Current Leases for Q1 2026 came in at $7.6 million, up 2.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (up 2.23% YoY), and the FY2025 annual result was $7.5 million, up 0.92% from the prior year.
• Current Leases improved to $7.6 million in Q1 2026 per IBRX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Current Leases peaked at $7.6 million in Q1 2026 and troughed at $1.4 million in Q3 2022.
• A 5-year average of $5.4 million and a median of $6.1 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2023: Current Leases sank 55.57% in 2022, then soared 326.21% in 2023.
• A 5-year view of Current Leases shows it stood at $2.6 million in 2022, then jumped by 97.89% to $5.2 million in 2023, then soared by 42.37% to $7.5 million in 2024, then advanced by 0.92% to $7.5 million in 2025, then rose by 1.21% to $7.6 million in 2026.
• Business Quant data shows IBRX's Current Leases at $7.6 million in Q1 2026, $7.5 million in Q4 2025, and $7.3 million in Q3 2025.